Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Deals
Features
News
Region
Sectors
Size
Uncategorised

Flotation/IPO

SinoHytec sets sights on $193m IPO
The Tsinghua University-backed hydrogen fuel engine producer has reportedly raised at least $67m of the $193m target for its initial public offering.
CureVac files for IPO
CureVac has filed for an initial public offering in the US, 20 years after being spun out of Eberhard Karls University of Tübingen.
iTeos takes $201m in flotation
Increasing both the number of shares and share price, iTeos Therapeutics has raised more than $201m in an offering that provided an exit to UCL and Ludwig Institute.
Nurix negotiates $209m IPO
Nurix Therapeutics, a Celgene-backed cancer treatment developer based on UC Berkeley and San Francisco research, priced shares above its range to raise $209m.
4D Molecular forgoes IPO option
UC Berkeley's genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.
Freeline progresses towards $100m IPO
UCL's gene therapy developer has followed a $120m round co-led by Novo three weeks ago by filing to go public on the Nasdaq Global Select Market.
Berkeley Lights beams on to public markets
UC Berkeley-linked cell biology technology developer Berkeley Lights floated in a $178m offering and its shares almost tripled in price on their first day of trading.
Relay receives $400m in initial public offering
The oncology therapy developer has gone public in an upsized offering that provided an exit to Third Rock Ventures.

Other News

Cambricon cashes $368m in IPO
CAS-backed AI processor provider Cambricon, valued at $2.5bn in 2018, floated on Shanghai's Star Market.
AlloVir approaches public markets
Baylor College spinout AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.
Nurix picks Nasdaq for $100m IPO filing
UC Berkeley and UC San Francisco-linked small molecule cancer drug developer Nurix Therapeutics has filed for an IPO on the Nasdaq Global Market.
Inozyme ignites IPO proceedings
Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.
Immatics completes $253m reverse merger
University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.
QuantumCTek to compute $102m IPO
QuantumCTek has filed for a $102m initial public offering, more than a decade after being spun out of University of Science and Technology of China.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg

Login